Esperion Therapeutics, Inc. (ESPR) News
Filter ESPR News Items
ESPR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ESPR News Highlights
- ESPR's 30 day story count now stands at 4.
- Over the past 11 days, the trend for ESPR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ESPR are DEC, CPRX and DRUG.
Latest ESPR News From Around the Web
Below are the latest news stories about ESPERION THERAPEUTICS INC that investors may wish to consider to help them evaluate ESPR as an investment opportunity.
Esperion to Participate in 42nd Annual J.P. Morgan Healthcare ConferenceANN ARBOR, Mich., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Sheldon Koenig, President and CEO, will deliver a corporate presentation on Wednesday, January 10, 2024, at 2:15 PM PT (5:15 PM ET). The Esperion management team will also be hosting investor meetings during the conference. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investor and med |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day off right with a look at the biggest pre-market stock movers to watch for Thursday morning! |
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet– Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use – – Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA Date of March 31; in Europe with Anticipated Approval in 1H 2024 – ANN ARBOR, Mich., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Food and Drug Administration (FDA) has approved an updated LDL-cholesterol lowering indication for NEXLETOL and NEXLIZET to in |
Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report?Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) Profit OutlookWith the business potentially at an important milestone, we thought we'd take a closer look at Esperion Therapeutics... |
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the Lowest Inflammation – – 21.6% Reduction in Vascular Inflammatory Marker High Sensitivity C-reactive Protein (hsCRP) in Patients Taking Bempedoic Acid – – Results Simultaneously Published in Circulation – ANN ARBOR, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Esper |
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023– Data from Randomized Control Trial Will Advance Evidence for Evaluation and Treatment of Heart Disease by Studying Actual Disease: Atherosclerosis – ANN ARBOR, Mich., Nov. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced participation in the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions. TRANSFORM is a randomized control trial – sponsored by Cleerly – that aims to enroll 7,500 patients who have pre-diabetes, type 2 diabetes, or metabolic syndr |
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)ANN ARBOR, Mich., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 8, 2023, the Company granted 18 new employees 141,800 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement |
Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong RevenuesEsperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023. |